GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
The conversation discusses a topical formula for hair loss including Finasteride (0.025%), Minoxidil (0.5%), Tretinoin (0.01%), Caffeine (0.005%), Melatonin (0.003%), Tea Tree Oil (0.05%), Aloe (0.05%), Biotin (0.05%), and Fagron TrichoXidil (2.5%). The user considers removing Minoxidil and Tretinoin to test TrichoXidil's effectiveness.
Using RU58841 and topical minoxidil together is fine and does not cancel out the benefits of each. Applying both treatments consecutively is acceptable.
Creating custom topical treatments for hair loss using minoxidil, finasteride, and RU58841. It includes recipes and instructions for home preparation, focusing on cost savings and customization.
Oral minoxidil can significantly increase eyelash length and thickness. Users report mixed results on hair growth, with some experiencing increased body hair.
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
A user discussed trying a hair loss product containing 10% Minoxidil and 1% Finasteride, noting it dries quickly and smells of alcohol. Other users commented that 10% Minoxidil might cause more irritation without added benefits compared to 5%.
Caffeine may promote hair growth and potentially inhibit 5-α-reductase activity in hair follicles, but its effectiveness and systemic impact remain unclear. Users discuss using topical caffeine solutions, with some experiencing no side effects compared to finasteride.